<?xml version="1.0" encoding="UTF-8"?>
<p id="para300">Since 2013, WHO has recommended a single dose of yellow fever vaccine for life-long immunity, and the amended International Health Regulations (2005) no longer require revaccination every 10 years.
 <xref rid="bib5" ref-type="bibr">5</xref>, 
 <xref rid="bib16" ref-type="bibr">16</xref> Although it followed evidence of long-term immunogenicity,
 <xref rid="bib17" ref-type="bibr">17</xref>, 
 <xref rid="bib18" ref-type="bibr">18</xref> this policy change has been controversial.
 <xref rid="bib19" ref-type="bibr">19</xref>, 
 <xref rid="bib20" ref-type="bibr">20</xref>, 
 <xref rid="bib21" ref-type="bibr">21</xref>, 
 <xref rid="bib22" ref-type="bibr">22</xref> The one-dose recommendation bypasses the question of the duration of protective immunity elicited in infants, the target population of immunisation programmes in endemic countries.
 <xref rid="bib6" ref-type="bibr">
  <sup>6</sup>
 </xref> Relevant studies have focused on adults or older children, but the duration of immunity against yellow fever following infant vaccination has been studied only over short post-vaccination periods of 1â€“3 months.
 <xref rid="bib23" ref-type="bibr">
  <sup>23</sup>
 </xref> The scarcity of long-term studies on neutralising antibodies elicited in vaccinated infants has been identified as a knowledge gap in regard to the need for booster doses of the yellow fever vaccine.
 <xref rid="bib23" ref-type="bibr">
  <sup>23</sup>
 </xref>
</p>
